Carisma Therapeutics Stock Price Prediction
| CARM Stock | 0.85 0.01 1.19% |
Oversold Vs Overbought
33
Oversold | Overbought |
EPS Estimate Next Quarter (0.18) | EPS Estimate Current Year (1.26) | EPS Estimate Next Year (0.77) | Wall Street Target Price 9.8 | EPS Estimate Current Quarter (0.26) |
Using Carisma Therapeutics hype-based prediction, you can estimate the value of Carisma Therapeutics from the perspective of Carisma Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Carisma Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Carisma because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Carisma Therapeutics after-hype prediction price | USD 0.86 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Carisma |
Carisma Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Carisma Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Carisma Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Carisma Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Carisma Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Carisma Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Carisma Therapeutics' historical news coverage. Carisma Therapeutics' after-hype downside and upside margins for the prediction period are 0.04 and 3.61, respectively. We have considered Carisma Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Carisma Therapeutics is relatively risky at this time. Analysis and calculation of next after-hype price of Carisma Therapeutics is based on 3 months time horizon.
Carisma Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Carisma Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Carisma Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Carisma Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 2.75 | 0.01 | 0.00 | 5 Events / Month | 10 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.85 | 0.86 | 1.18 |
|
Carisma Therapeutics Hype Timeline
Carisma Therapeutics is currently traded for 0.85. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of 0.0. Carisma is projected to increase in value after the next headline, with the price projected to jump to 0.86 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 1.18%, whereas the daily expected return is currently at -0.22%. The volatility of related hype on Carisma Therapeutics is about 20625.0%, with the expected price after the next announcement by competition of 0.85. The company reported the previous year's revenue of 14.92 M. Net Loss for the year was (86.88 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next projected press release will be in about 5 days. Check out Carisma Therapeutics Basic Forecasting Models to cross-verify your projections.Carisma Therapeutics Related Hype Analysis
Having access to credible news sources related to Carisma Therapeutics' direct competition is more important than ever and may enhance your ability to predict Carisma Therapeutics' future price movements. Getting to know how Carisma Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Carisma Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CNSP | Cns Pharmaceuticals | (0.01) | 6 per month | 0.00 | (0.06) | 9.09 | (8.33) | 39.29 | |
| ZVSA | ZyVersa Therapeutics | (0.01) | 5 per month | 0.00 | (0.15) | 7.57 | (9.60) | 78.93 | |
| EFTR | Effector Therapeutics | (0.06) | 4 per month | 0.00 | (0.31) | 8.70 | (27.78) | 88.91 | |
| VECT | VectivBio Holding AG | 0.06 | 7 per month | 0.88 | 0.19 | 5.61 | (3.08) | 39.30 | |
| AVRO | AVROBIO | 0.05 | 5 per month | 1.89 | 0.01 | 4.11 | (3.17) | 14.20 | |
| IMMX | Immix Biopharma | (0.04) | 4 per month | 4.54 | (0.01) | 9.38 | (8.22) | 32.68 | |
| HEPA | Hepion Pharmaceuticals | 0.05 | 3 per month | 0.00 | (0.05) | 8.06 | (8.11) | 33.54 | |
| SRNEQ | Sorrento Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ZURA | Zura Bio Limited | (0.21) | 9 per month | 0.00 | (0.10) | 7.95 | (7.94) | 26.70 | |
| CYTO | Altamira Therapeutics | (0.01) | 7 per month | 0.00 | (0.24) | 7.32 | (10.87) | 22.81 | |
| ENVB | Enveric Biosciences | (0.01) | 7 per month | 0.00 | (0.15) | 6.25 | (7.50) | 28.33 | |
| PALI | Palisade Bio | 0.03 | 6 per month | 0.00 | (0.12) | 5.97 | (8.55) | 24.25 |
Carisma Therapeutics Additional Predictive Modules
Most predictive techniques to examine Carisma price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Carisma using various technical indicators. When you analyze Carisma charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Carisma Therapeutics Predictive Indicators
The successful prediction of Carisma Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Carisma Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Carisma Therapeutics based on analysis of Carisma Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Carisma Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Carisma Therapeutics's related companies. | 2023 | 2024 (projected) | Interest Debt Per Share | 0.0577 | 0.0548 | Revenue Per Share | 0.45 | 0.42 |
Story Coverage note for Carisma Therapeutics
The number of cover stories for Carisma Therapeutics depends on current market conditions and Carisma Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Carisma Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Carisma Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Carisma Therapeutics Short Properties
Carisma Therapeutics' future price predictability will typically decrease when Carisma Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Carisma Therapeutics often depends not only on the future outlook of the potential Carisma Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Carisma Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.5 M | |
| Cash And Short Term Investments | 77.6 M |
Check out Carisma Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.